ABBV · News · 20260909N
Acquisition / Partnership / Divestiture
AbbVie Inc. · 2026-09-09 · Importance 61 · Surprise 60 · In source text
AbbVie issued US$10 billion of bonds in August to help fund its US$10.9 billion all-cash acquisition of Apogee Therapeutics. The nine tranches mature between 2028 and 2066 and may also fund general corporate purposes and potential debt repayment. The issuance received an A- rating from S&P Global, while Moody’s had upgraded AbbVie to A2 earlier in 2026, increasing long-term debt obligations associated with the transaction.
Key facts
- AbbVie issued US$10 billion in bonds in August across nine tranches to fund its US$10.9 billion all-cash acquisition of Apogee Therapeutics. source
- The notes are due between 2028 and 2066. source
- Moody's upgraded AbbVie to A2 earlier in the year. source
- Proceeds from the bonds will also cover general corporate purposes and potential debt repayment. source
- The bonds received an A- rating from S&P Global. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | committed | +6.9% | AbbVie issued US$10 billion in bonds in August across nine tranches to fund its US$10.9 billion all-cash acquisition of Apogee Therapeutics. |
| cash | negative | committed | -6.9% | AbbVie issued US$10 billion in bonds in August across nine tranches to fund its US$10.9 billion all-cash acquisition of Apogee Therapeutics. |
| liability | negative | committed | -6.3% | AbbVie issued US$10 billion in bonds in August across nine tranches to fund its US$10.9 billion all-cash acquisition of Apogee Therapeutics. |
| cash | positive | committed | +6.3% | AbbVie issued US$10 billion in bonds in August across nine tranches to fund its US$10.9 billion all-cash acquisition of Apogee Therapeutics. |